All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
NICE recommendation of acalabrutinib for patients with treatment-naïve CLL
By Sumayya Khan
Bookmark this article
On March 18, 2021, it was announced that the National Institute for Health and Care Excellence (NICE) in England recommend the use of acalabrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia (CLL).
This recommendation is for patients with a TP53 mutation or 17p deletion, or for patients without these mutations but where fludarabine plus cyclophosphamide and rituximab, or bendamustine plus rituximab is unsuitable. As acalabrutinib is administered as a twice daily tablet, the recommendation is of particular benefit during the current COIVD-19 pandemic because patients can self-administer from home.
This recommendation comes after the European approval previously discussed on the Lymphoma Hub.
- Chemotherapy-free treatment option to be offered to patients with England’s most common leukaemia. https://www.nice.org.uk/news/article/chemotherapy-free-treatment-option-to-be-offered-to-patients-with-england-s-most-common-leukaemia. Published Mar 18, 2021. Accessed Mar 19, 2021.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
55 votes - 66 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox